Ramesh Ramachandran1*, Julaina Abd Jalil1
1. Inborn Errors of Metabolism (IEM) & Genetics Unit, Nutrition, Metabolic & Cardiovascular Research Centre, Institute for Medical Research, National Institutes of Health, Setia Alam, Ministry of Health Malaysia
*Corresponding author: Ramesh Ramachandran.
ABSTRACT
INTRODUCTION: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral disturbances. Its pathology involves amyloid-beta (Aβ) plaque accumulation, tau protein hyperphosphorylation, and cholinergic system dysfunction. Key enzymes such as beta-secretase 1 (BACE1), acetylcholinesterase (AChE), and glycogen synthase kinase-3β (GSK-3β) are centrally implicated in these mechanisms and represent prime therapeutic targets. Bacopa monnieri (Brahmi), a traditional Ayurvedic medicinal plant, is rich in triterpenoid saponins—particularly the Bacoside A family—known for neuroprotective, antioxidant, and cognitive-enhancing properties.
OBJECTIVE(S): This study aims to investigate the binding potential of four Bacopa monnieri-derived saponins: Bacosaponin C, Bacopaside II, Bacopaside X, and Bacoside A3 against multiple AD-associated protein targets using molecular docking.
MATERIALS & METHODS: The target proteins selected for docking were BACE1 (PDB ID: 1W50), cyclin-dependent kinase 5 (CDK5/p25) (3O0G), AChE (4EY7), GSK-3β (4ACD), and amyloid-beta fibrils (5OQV). Ligand structures were retrieved from PubChem and processed using Open Babel and AutoDock Tools. Molecular docking was conducted using AutoDock Vina, and interactions were visualized using PyMOL and Discovery Studio Visualizer.
RESULTS: We developed an in-house automated docking workflow by running a single script to dock multiple ligands against one target. Using this workflow, we found that Bacopaside II exhibited the strongest binding to AChE with a docking score of −9.377 kcal/mol. Bacosaponin C demonstrated strong binding to BACE1 and GSK-3β. Interaction analysis revealed key binding residues such as Arg128 (BACE1), Ser293 (AChE), and Tyr216 (GSK-3β), involved in hydrogen bonding and hydrophobic interactions.
CONCLUSION: In conclusion, Bacopaside II and Bacosaponin C show promising multi-target interaction profiles with key proteins implicated in AD. These findings support the potential role of Bacopa monnieri saponins as natural therapeutic candidates for multi-pathway intervention in Alzheimer’s disease.
KEYWORDS: Alzheimer’s Disease, Bacopa monnieri, Molecular Docking, Saponins, Multi-Target Inhibition


